Developing Programs Across Three Distinct Platforms: Oral Delivery, Therapeutics and Regenerative Medicine

The initial focus of development is on PT-1 and TOP-1 programs.  Each of these programs aim to deliver a breakthrough solution where other approaches have failed or do not exist.

ProgramDiscoveryPre-ClinicalPhase 1
Oral Delivery
Platform
PT-1 EPO
Discovery
Pre-Clinical
Phase 1
PT-2 Octreotide
Discovery
Pre-Clinical
Phase 1
PT-3 GLP-1 Agonist
Discovery
Pre-Clinical
Phase 1
TherapeuticsTop-1 Skin Graft (Donor)
Discovery
Pre-Clinical
Phase 1
Top-2 Diabetic Wound
Discovery
Pre-Clinical
Phase 1
Top-3 Burns (2nd Degree)
Discovery
Pre-Clinical
Phase 1
Regenerative
Medicine
AIPC
Discovery
Pre-Clinical
Phase 1
T1 Diabetes Autologous Transplant
Discovery
Pre-Clinical
Phase 1
Key
2021-2022
2022-2023

Research & Development Engine

Powering New Discovery

Imagine’s three platforms form the foundation of a multi-year scientific inquiry that will lead to many discoveries and therapies to benefit a multitude of patients.  With research programs targeting diseases where there are currently ineffective or no treatments, Imagine Pharma is pushing the boundaries of what is possible.

We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.

R & D EngineDiscoveryPre-ClinicalPhase 1
2nd Generation Oral Delivery System
Discovery
Pre-Clinical
Phase 1
Additional Oral Biologics
Discovery
Pre-Clinical
Phase 1
Comprehensive Lung Healing Initiative
Discovery
Pre-Clinical
Phase 1
Comprehensive Bowel Initiative
Discovery
Pre-Clinical
Phase 1
Personalized Blood
Vessel
Discovery
Pre-Clinical
Phase 1